「All in One」单动脉/血管技术行TAVR的安全性与有效性
回顾性纳入北京安贞医院2021年8至12月连续30例采用「All in One」单动脉/血管技术行TAVR的患者,分析基线、手术及术后1个月结局。结果显示无术中死亡、瓣膜移位、转外科或冠脉闭塞,无心肌梗死或卒中,瓣膜工作良好且症状改善。
要点
- 单动脉/血管技术行TAVR安全可行,围术期无严重并发症。
- 26例主动脉瓣狭窄患者跨瓣压差由50.4±16.0 mmHg降至9.4±3.2 mmHg。
- 术后1个月KCCQ评分由48.1±18.4升至73.5±17.6。
核心结论
- 初步证实使用「All in One」单动脉/血管技术行TAVR安全可行,有利于减少外周血管相关并发症。
研究设计与样本
- 回顾性研究,连续纳入2021年8至12月于北京安贞医院采用「All in One」单动脉/血管技术行TAVR的30例患者。
- 收集住院期间临床基线、手术资料、术后结果及住院和术后1个月不良事件。
主要发现
- 患者年龄(72.6±9.7)岁,男性16例,STS评分(4.73±3.12)%。
- 单纯主动脉瓣反流4例(均为三叶式),主动脉瓣狭窄26例(三叶式10例,二叶式16例)。
- 单血管技术3例(均为主动脉瓣狭窄),单动脉技术27例。
- 术后即刻超声无/微量瓣周漏27例,少量瓣周漏3例。
- 26例狭窄患者跨瓣压差由(50.4±16.0)mmHg降至(9.4±3.2)mmHg(P<0.001),手术时间(64.8±18.9)min。
临床怎么用
- 该技术可用于主动脉瓣狭窄及单纯主动脉瓣反流患者的TAVR,围术期严重并发症少。
- 术后1个月瓣膜功能良好且症状显著改善,支持推广使用以减少血管入路并发症。
局限性
- 本研究为单中心回顾性研究,样本量30例,随访仅1个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the safety and efficacy of transcatheter aortic valve replacement (TAVR) using the "All in One" single-artery/vessel technique. Methods: This is a retrospective study. A total of 30 consecutive patients underwent TAVR using the single artery/vascular technique in Beijing Anzhen Hospital from August to December 2021 were included. Baseline clinical data, operative situation, postoperative outcomes, and incidence of adverse events during hospitalization and at one month post TAVR were analyzed. Results: Mean age was (72.6±9.7) years, 16 were male patients, STS score was (4.73±3.12)%. Four patients were diagnosed as isolated aortic regurgitation (all with tricuspid aortic valves), and 26 patients were diagnosed as aortic stenosis (AS), 10 of whom with tricuspid aortic valves and 16 of whom with bicuspid aortic valves. The single-vessel technique was applied in 3 aortic stenosis cases; the single-artery technique was applied in 27 cases. Echocardiography was performed immediately after procedure and results showed no or trace perivalvular leak in 27 cases and small perivalvular leak in 3 cases; the mean aortic transvalvular gradient of 26 AS patients decreased from (50.4±16.0) mmHg (1 mmHg=0.133 kPa) to (9.4±3.2) mmHg (P<0.001). The procedure time was (64.8±18.9) min. There were no intraoperative death, valve displacement, conversion to surgery, coronary artery occlusion in all 30 patients. There were no major cardiac adverse events such as myocardial infarction or stroke occurred during hospitalization or at follow-up. One-month follow-up echocardiography indicated prosthesis works well. The symptoms were significantly alleviated, and the Kansas City Cardiomyopathy Score (KCCQ score) of all patients increased from 48.1±18.4 to 73.5±17.6 (P<0.001). Conclusions: TAVR using the single artery/vessel technique is safe and feasible. This technique is related to reduced access complications and worthy of wide application. 目的: 初步探索使用“All in One”单动脉/血管技术行经导管主动脉瓣置换术(TAVR)的安全性和有效性。 方法: 本研究为回顾性研究,连续收集2021年8至12月于北京安贞医院采取“All in One”单动脉/血管技术行TAVR治疗的患者。收集患者住院期间的临床基线资料、手术资料、术后结果、住院期间及术后1个月不良事件发生情况。 结果: 共纳入30例患者,其中男性16例,年龄为(72.6±9.7)岁,(美国)胸外科医师学会(STS)评分(4.73±3.12)%。单纯主动脉瓣反流患者4例,均为三叶式主动脉瓣;主动脉瓣狭窄患者26例,其中三叶式主动脉瓣10例,二叶式主动脉瓣16例。应用“All in One”单血管技术3例,均为主动脉瓣狭窄患者;“All in One”单动脉技术27例。术后即刻超声心动图检查提示无/微量瓣周漏27例,少量瓣周漏3例;26例狭窄患者主动脉瓣跨瓣压差由术前的(50.4±16.0)mmHg(1 mmHg=0.133 kPa)下降至(9.4±3.2)mmHg(P<0.001);手术时间为(64.8±18.9)min。30例患者术中均未出现死亡、瓣膜移位、转外科手术、冠状动脉闭塞、血管入路夹层破裂等并发症;住院期间及随访期间患者未出现心肌梗死、卒中等主要心脏不良事件。患者出院后1个月随访超声心动图结果提示瓣膜工作良好,症状均有明显改善,堪萨斯城心肌病调查问卷(KCCQ)评分由术前的48.1±18.4升至73.5±17.6(P<0.001)。 结论: 初步证实使用“All in One”单动脉/血管技术行TAVI安全可行,有利于减少外周血管相关并发症,值得普及推广。.
引用
- Yao J, Liu XM, Yuan F, et al. [Safety and efficacy of transcatheter aortic valve replacement using the "All in One" single artery/vessel technique]. Zhonghua Xin Xue Guan Bing Za Zhi. 2023. PMID: 37709717. doi:10.3760/cma.j.cn112148-20230807-00058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。